Summit Therapeutics doses first patient in antibiotic trial

Writer, Stock Market Wire
Wednesday, February 13, 2019 - 13:10

Summit Therapeutics said it had dosed the first patient in the third phase of a clinical trial of an antibiotic to treat C.difficile infection.

The treatment, ridinilazole, had achieved statistical superiority over the standard of care, vancomycin, in the phase-two clinical trial.

'With positive results, we believe ridinilazole could be positioned as the drug of choice in the front-line treatment of C.difficile infection, which potentially provides patients with sustained cures and hospitals with compelling cost savings,' chief executive Glyn Edwards said.

At 1:10pm: (LON:SUMM) Summit Therapeutics PLC share price was +0.5p at 23.5p


Related content

Summit Therapeutics presents antibiotic concept data at Amsterdman conference

Summit Therapeutics said it had presented proof of concept data for a series of new antibiotics at a conference in Amsterdam.

The data was presented...

Mon, 15/04/2019 - 08:06


Summit Therapeutics swings to profit

Summit Therapeutics swung to an annual profit as it continued to develop its antibiotic portfolio.

Pre-tax profit for the year through amounted to £5.0m, compared...

Wed, 27/03/2019 - 13:22


Summit Therapeutics says shares from $25m raising to be admitted imminently

Summit Therapeutics said the admission of new shares in the company connected with its proposed $25m capital raising was expected to occur on or around...

Tue, 08/01/2019 - 08:09


Summit Therapeutics CFO Erik Ostrowski to stand down

Antibiotic developer Summit Therapeutics said chief financial officer Erik Ostrowski would leave at the end of December to pursue another opportunity.

The company said it...

Mon, 17/12/2018 - 07:21


Summit Therapeutics losses deepen as expenses rise

Summit Therapeutics posted a deeper third-quarter loss underpinned by higher R&D spending and expenses related to payments to executives.

Pre-tax losses for the three months...

Tue, 11/12/2018 - 13:43